In several rodent models of drug-resistant epilepsy, blockade of the COX-2–PGE2 pathway and prostaglandin E receptor 2 (EP2) transitory inhibition reduced the degree of BBB dysfunction, decreasing the level of cytokine production and causing reactive gliosis and seizure-promoted functional deficits appear, having a role in the anti-inflammatory cascade and neuroprotection [22]. Here, PTGER2 is linked to epilepsy.